Tyra Biosciences to Present at Upcoming Investor Conferences

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

News Market Reaction – TYRA

The recorded move for TYRA in the trading session of this news was +1.17%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/27/2024 - 04:05 PM EST

CARLSBAD, Calif., Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate in the following investor conferences:

TD Cowen's 44^th Annual Healthcare Conference, March 4-6th: Todd Harris, CEO of TYRA, will present a company overview on Wednesday, March 6, 2024, at 2:10 pm ET. TYRA management will also participate in one-on-one meetings with investors during the conference.
Jefferies Biotech On the Bay Summit, March 11-13th: TYRA management will participate in one-on-one meetings with investors during the conference.
Barclays 26^th Annual Global Healthcare Conference, March 12-14^th: Todd Harris, CEO of TYRA, will participate in a fireside chat on Thursday, March 14^th, 2024, at 8:00 am ET. TYRA management will also participate in one-on-one meetings with investors during the conference.

A live and archived webcast of the Cowen presentation and Barclays fireside chat will be available via the For Investors page on the Investor section of the TYRA website.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:
Amy Conrad
aconrad@tyra.bio